Shattuck Labs

Shattuck Labs is a clinical-stage biotechnology company focused on developing a new class of biologic medicine for the treatment of cancer and autoimmune diseases. They are pioneering the development of bi-functional fusion proteins using their proprietary Agonist Redirected Checkpoint (ARC®) platform. ARC molecules simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic, offering a novel approach to treatment. Their lead program, SL-172154, is designed to block the CD47 immune checkpoint and simultaneously activate the CD40 receptor, and is currently being evaluated in multiple Phase 1 clinical trials for patients with AML, HR-MDS, and PROC.

Shattuck Labs was founded in 2016 and has grown rapidly, attracting significant funding and advancing their lead asset from discovery to clinical trials within two years. Driven by a team of experienced scientists and clinicians, the company prioritizes scientific excellence, thoughtful resource management, and a sense of urgency to translate innovative ideas into life-improving medicines for patients with serious diseases.

Shattuck Labs offers a competitive benefits package that includes a generous PTO plan and paid family leave. This allows employees to take time off to recharge and spend time with their families. The company is also headquartered in Austin, Texas, which is a highly desirable location for many professionals.

Shattuck Labs offers a comprehensive benefits package to its employees, including competitive pay with performance-based bonuses and stock options. They provide a choice of medical, vision, and dental plans from high-quality providers and offer a 401(k) with a robust matching plan. Shattuck Labs also provides income protection through employer-paid life insurance and long-term disability coverage, as well as generous PTO and paid family leave, demonstrating their commitment to employee well-being and work-life balance.

Shattuck Labs is a clinical-stage biotechnology company dedicated to developing innovative bi-functional fusion proteins as a new class of biologic medicine. Their mission is to create novel therapeutics for patients with cancer and autoimmune diseases by leveraging their proprietary Agonist Redirected Checkpoint (ARC®) technology. This platform allows them to simultaneously inhibit immune checkpoint molecules and activate costimulatory molecules within a single therapeutic, offering a unique approach to bolstering the immune system’s fight against disease. Shattuck Labs prioritizes scientific excellence and thoughtful resource management to translate their innovative ideas into medicines that improve the lives of patients with serious diseases.

Shattuck Labs cultivates a culture of urgency, scientific excellence, and compassion. They value bold innovation, respect for diverse perspectives, honest communication, and a balanced approach to achieving success. Their mission is deeply personal, driven by a desire to improve the lives of patients and employees alike through meaningful work. They strive to create a supportive environment where individuals can unleash their potential and contribute to the development of groundbreaking therapies.

Shattuck Labs prioritizes diversity, equity, and inclusion by actively seeking out and hiring a diverse workforce. The company emphasizes respect, honesty, and balance in its core values and demonstrates its commitment to these values through its benefits package, which includes competitive pay, performance-based bonuses, and equity incentives. Shattuck Labs also encourages employees to take time off to recharge and spend time with family, offering generous paid time off and a paid family leave plan.